Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Dec 12 2023

Full Issue

Viewpoints: New Sickle Cell Treatment Hits A Roadblock; Texas Proves Abortion Ban Exemptions Are A Joke

Editorial writers discuss the new sickle cell treatment, the farce of abortion ban exemptions, LGBTQ+ health and more.

Stat: CRISPR Treatments For Sickle Cell Won’t Be Enough For All Patients

After decades of limited progress in the treatment of sickle cell disease (SCD), both patients and physicians are on the verge of monumental change. On Friday, the Food and Drug Administration approved Vertex/CRISPR Therapeutics’ Casgevy and Bluebird Bio’s Lyfgenia, the first one-time gene therapies that will treat the underlying cause of SCD rather than just the symptoms. They are the first therapeutic treatments using CRISPR gene editing technology approved by the FDA for any medical condition. (Robert Brodsky, 12/12)

The New York Times: A Texas Case Shows That Abortion Ban Exemptions Are A Sham 

Soon after the Supreme Court overturned Roe v. Wade last year, horror stories started emerging of women denied medically urgent abortions for pregnancies gone dangerously awry. In response, the anti-abortion movement developed a sort of conspiracy theory to rationalize away the results of their policies. (Michelle Goldberg, 12/11)

The Washington Post: Texas Abortion Case Undermines Rationale For Abortion Bans 

Abortion rights activists, medical professionals and ordinary women warned the Supreme Court in advance of the Dobbs v. Jackson Women’s Health Organization decision: Legislatures cannot dictate medical decisions without creating horrendous injustices and medical travesties. (Jennifer Rubin, 12/11)

Newsweek: The Health Information Gap Is Making LGBTQ Americans Sick 

LGBTQ Americans have long experienced discrimination, stigmas, and exclusion in the health care system. In a survey last year, nearly a quarter (24 percent) said that during a doctor's appointment, they were blamed for their own health problems, compared to only 9 percent of non-LGBTQ respondents. And 16 percent said they were denied medical services; less than half as many non-LGBTQ respondents said the same. (Tayla Mahmud and Mark Westall, 12/8)

The Washington Post: These Three Simple Lifestyle Changes Can Add Years To People's Lives

Over the past year, I’ve been reporting on how artificial intelligence can improve patient safety, enhance diagnosis and expand access to care. While technological innovations offer great promise in medicine, let’s not forget about low-tech solutions that have been shown again and again to improve health and add years to people’s lives. (Leana S. Wen, 12/12)

Stat: CMS Should Re-Evaluate The Medicare Annual Wellness Visit 

In 2011, the Centers for Medicare and Medicaid Services created the annual wellness visit (AWV), a new visit type with no cost to Medicare patients, better reimbursement to primary care practices, and higher assigned credit for clinicians’ work. The visit takes about 30 minutes and includes a questionnaire covering home safety, falls risk, and ability to perform activities of daily living, along with a survey of recommended preventive services and depression and dementia screening. No physical assessment is required beyond vision screening and vital signs. (Jeffrey Millstein, 12/12)

Newsweek: Biden's Health Care Agenda Will Make A Broken System Worse 

With President Joe Biden stumbling in the polls, the White House is searching for a strategy to stabilize itself leading into the 2024 election. And according to recent reporting, the administration is betting on elevating health care reform as a key campaign platform to shore up support and enthusiasm. (Tom Price and Elaine Parker, 12/11)

Stat: The Woman Behind The Dana Farber-Brigham & Woman's Breakup

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks. (Shirley Leung, 12/11)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF